(Q36781452)

16 August 2017

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib (English)

1 reference

16 August 2017

squamous cell carcinoma

1 reference

5

Patrick Hwu

1 reference

16 August 2017

Zita Dubauskas

1

1 reference

16 August 2017

Joy Kunishige

2

1 reference

16 August 2017

Victor G Prieto

3

1 reference

16 August 2017

Eric Jonasch

4

1 reference

16 August 2017

Nizar M Tannir

6

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Clinical Genitourinary Cancer

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

1

1 reference

16 August 2017

20-23

1 reference

Sorafenib in advanced hepatocellular carcinoma

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Sorafenib in advanced clear-cell renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Keratoacanthomas associated with sorafenib therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Cutaneous side-effects of kinase inhibitors and blocking antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Mycosis fungoides-like reaction in a patient treated with Gleevec

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4825856

Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification--part two

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19213663

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19213663

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3816/CGC.2009.N.003

1 reference

release_fzlgn4lo5ncutoqegtna26ktxq

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fzlgn4lo5ncutoqegtna26ktxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

16 August 2017

PubMed publication ID

19213663

1 reference